Bosutinib received US FDA and EU European Medicines Agency approval on September 4, 2012 and 27 March, 2013 respectively for the treatment of adult patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.
Philadelphia | Philadelphia Eagles | Philadelphia Phillies | Philadelphia Orchestra | It's Always Sunny in Philadelphia | The Philadelphia Inquirer | Philadelphia Museum of Art | Philadelphia Flyers | Philadelphia 76ers | Philadelphia Bulletin | X chromosome | Philadelphia Union | Children's Hospital of Philadelphia | Philadelphia (film) | Northeast Philadelphia | Y chromosome | West Philadelphia | Philadelphia Wings | Philadelphia Zoo | Philadelphia Daily News | Center City, Philadelphia | 1960 Philadelphia Eagles season | Wells Fargo Center (Philadelphia) | Philadelphia Theatre Company | Philadelphia International Airport | Philadelphia City Hall | North Philadelphia | University of the Arts (Philadelphia) | Kensington, Philadelphia | Free Library of Philadelphia |
Tyrosine kinase inhibitors such as imatinib (marketed as Gleevec) have been developed to treat chronic myeloid leukemia (CML), in which the BCR-ABL fusion gene (the product of a reciprocal translocation between chromosome 9 and chromosome 22) is present in >95% of cases and produces hyperactivated abl-driven protein signaling.